IMPACT OF ABCB1 AND CES1 GENETIC POLYMORPHISMS ON TROUGH STEADY-STATE DABIGATRAN CONCENTRATIONS IN PATIENTS AFTER ENDOPROSTHESIS OF KNIFE JOIN
D. A. Sychev,
A. N. Levanov,
T. V. Shelekhova,
P. O. Bochkov,
N. Р. Denisenko,
K. A. Ryzhikova,
K. В. Mirzaev,
E. A. Grishina,
M. A. Gavrilov
Affiliations
D. A. Sychev
Russian Medical Academy of Continuous Professional Education FGBOU DPO of the Ministry of Health of Russia
A. N. Levanov
V.I. Razumovsky Saratov State Medical University FGBOU VO of the Ministry of Health of Russia
T. V. Shelekhova
V.I. Razumovsky Saratov State Medical University FGBOU VO of the Ministry of Health of Russia
P. O. Bochkov
Russian Medical Academy of Continuous Professional Education FGBOU DPO of the Ministry of Health of Russia; Research Centre of Russian Medical Academy of Continuous Professional Education (pharmacokinetics)
N. Р. Denisenko
Russian Medical Academy of Continuous Professional Education FGBOU DPO of the Ministry of Health of Russia; Research Centre of Russian Medical Academy of Continuous Professional Education (pharmacokinetics)
K. A. Ryzhikova
Russian Medical Academy of Continuous Professional Education FGBOU DPO of the Ministry of Health of Russia; Research Centre of Russian Medical Academy of Continuous Professional Education (pharmacokinetics)
K. В. Mirzaev
Russian Medical Academy of Continuous Professional Education FGBOU DPO of the Ministry of Health of Russia; Research Centre of Russian Medical Academy of Continuous Professional Education (pharmacokinetics)
E. A. Grishina
Russian Medical Academy of Continuous Professional Education FGBOU DPO of the Ministry of Health of Russia; Research Centre of Russian Medical Academy of Continuous Professional Education (pharmacokinetics)
M. A. Gavrilov
Research Institute of Traumatology, Orthopedics and Neurosurgery of V.I. Razumovsky Saratov State Medical University FGBOU VO of the Ministry of Health of Russia
Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2]. Dabigatran etexilate is a direct inhibitor of thrombin used as a prophylaxis of venous thromboembolic events (VTE) in Europe and Russia. [3]. This study evaluated the impact of ABCB1 and CES1 genetic polymorphisms on the peak and residual dabigatran concentration in orthopedic patients. Material and methods: A total of 30 patients aged 43 to 77 years following knee joint replacement were enrolled in the study. All patients received dabigatran etexilate at a dose of 220 mg/day for the prevention of VTEO. ABCB1 and CES1 genetic polymorphism genotyping was performed by real-time polymerase chain reaction (PCR). The peak and residual concentrations of dabigatran were determined by high-performance liquid chromatography (HPLC). Results: It was found that the ТТ genotype of the MDR1 gene С3435Т polymorphism is associated with a higher peak concentration of dabigatran than the CC genotype (p <0.1). Statistically significant results for CES1 gene rs2244613 polymorphism were obtained in patients younger than 60 years (p <0.05). The analysis of the haplotypes combination in two polymorphisms showed that the most common haplotype combination CC (rs1045642) ABCB1/CT (rs2244613) CES1 was significantly associated with a higher peak concentration of dabigatran compared to the rest of haplotype combinations (p = 0.002). Conclusions: The examination of a cohort of patients receiving dabigatran for the prevention of VTE during the period of large joints arthroplasty showed that SNPs C3435T ABCB1 and rs2244613 CES1 could play an important role in changing dabigatran concentrations. No data suggestive of the impact of SNP ABCB1 rs4148738 on the peak concentration of dabigatran were received.
